Skip to content

Tirzepatide (GLP-1/GIP dual agonist)

Clinical evidence

Tirzepatide is a first-in-class dual GLP-1/GIP receptor agonist. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). SURMOUNT trials showed 20–25% body weight reduction — among the highest of any approved agent. Weekly dosing with 5-week dose escalation. Not medical advice; consult a provider.

How Tirzepatide (GLP-1/GIP dual agonist) works

Tirzepatide activates both GLP-1 and GIP receptors, offering a distinct mechanism from semaglutide. Only use under a healthcare provider's care; not for self-directed use.

Researched benefits

  • •Dual GLP-1/GIP mechanism — first-in-class
  • •FDA-approved for type 2 diabetes and chronic weight management
  • •SURMOUNT trials: 20–25% body weight reduction
  • •Weekly dosing with 5-week escalation schedule
  • •Side effect profile similar to GLP-1s; may have slightly higher GI tolerability in some studies

What it is studied for

  • •Type 2 diabetes management
  • •Chronic weight management when prescribed
  • •Metabolic health where dual agonist mechanism is appropriate

Reported side effects and cautions

  • •Nausea, vomiting, diarrhea (similar to GLP-1 agonists)
  • •Risk of pancreatitis; contraindications exist
  • •Requires prescription and medical supervision

Dosing protocol described in the literature

Dosage
Per prescription
Frequency
Weekly
Administration
Subcutaneous
Cycle
Ongoing per provider

Metabolic & weight support

Work out the reconstitution for this dose →

Evidence rating: Clinical evidence

Studied in human clinical trials. Some compounds in this tier are approved medicines for specific indications and require a prescription.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)CagrilintideRetatrutide + Cagrilintide (combination)GHK-CU

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Tirzepatide (GLP-1/GIP dual agonist). Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.